Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice

Cell Reports(2021)10.1016/j.celrep.2021.109450Source: DataRank Database

Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice is a research paper published in Cell Reports (2021). On theSindex it has a DataRank of 0. It has been cited 47 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access47 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (11 grants)Impact (FWCI 2.73)OA: goldTopics (53)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (15)

Alexandra Schäfer ORCID,Sarah R. Leist ORCID,Dapeng Li ORCID,Kendra L. Gully ORCID,Boyd L. Yount ORCID

Live enrichment

PubMed:34289384 PMC:PMC8270748 OpenAlex:https://openalex.org/W3178932731

NIAID NIH HHS

Grant: R01 AI132178

NCI NIH HHS

Grant: P30 CA016086

NIAID NIH HHS

Grant: T32 AI007151

NIAID NIH HHS

Grant: F32 AI152296

National Institutes of Health

Grant: 1F32AI152296-01A1

Defining viral and immune mechanisms of Dengue virus serotype 2 immune evasion

National Institutes of Health

Grant: 5P30CA016086-41

Cancer Center Support Grant

National Institutes of Health

Grant: 5R01AI132178-05

Broad-spectrum antiviral GS-5734 to treat MERS-CoV and related emerging CoV

National Institutes of Health

Grant: 5T32AI007151-42

Infectious Disease Pathogenesis Research Training Program

National Institutes of Health

National Cancer Institute

National Institute of Allergy and Infectious Diseases

FWCI

2.73

Citation Percentile

0.9%

Citation Trend

2021

2022

2023

2024

2025

goldLicense: cc-by

journalhttps://www.cell.com/cell-reports/pdf/S2211-1247(21)00867-6.pdf

publisherhttps://www.cell.com/cell-reports/pdf/S2211-1247(21)00867-6.pdf

publisherhttps://api.elsevier.com/content/article/PII:S2211124721008676?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2211124721008676?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.celrep.2021.109450

Fields of Study

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 detection and testing0303 health sciences03 medical and health sciencesAnimalsAntibodies, MonoclonalAntiviral AgentsHumansMiceSARS-CoV-2COVID-19 Drug Treatment

MeSH Terms

SARS-CoV-2COVID-19 Drug TreatmentAnimalsAntibodies, MonoclonalAntiviral AgentsHumansMice

Keywords

Monoclonal antibodyMedicineAntibodyIn vivoClinical trialSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)DiseaseVirologyCombination therapyImmunologyClinical efficacyPharmacologyInfectious disease (medical specialty)BiologyInternal medicineBiotechnologyMonoclonal antibodiesVariantsTherapyRdvRemdesivirCovid-19Sars-cov-2B.1.351QH301-705.5Antibodies, MonoclonalAntiviral AgentsArticleCOVID-19 Drug TreatmentMiceAnimalsHumansBiology (General)

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice

FAIR Checklist

Authors (15)

Funding (11 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)